Sarepta Therapeutics (SRPT) Short-term Investments (2013 - 2026)

Sarepta Therapeutics' Short-term Investments history runs 14 years deep, the most recent figure standing at $188.7 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 33.05% year-over-year to $188.7 million; the TTM figure through Mar 2026 stood at $188.7 million (down 33.05% YoY), while the FY2025 annual figure was $138.4 million, down 45.04% from the prior year.
• Short-term Investments for Q1 2026 stood at $188.7 million, up from $138.4 million in the prior quarter.
• The five-year high for Short-term Investments was $1.2 billion in Q4 2023, with the low at $44.6 million in Q3 2024.
• The 5-year median for Short-term Investments is $963.5 million (2024), against an average of $695.7 million.
• The sharpest annual moves came in 2022 and 2024: Short-term Investments soared 3431.67% in 2022, then sank 96.26% in 2024.
• Sarepta Therapeutics' Short-term Investments stood at $1.0 billion in 2022, then increased by 22.02% to $1.2 billion in 2023, then plunged by 79.82% to $251.8 million in 2024, then plunged by 45.04% to $138.4 million in 2025, then jumped by 36.4% to $188.7 million in 2026.
• Business Quant data shows SRPT's Short-term Investments at $188.7 million in Q1 2026, $138.4 million in Q4 2025, and $237.9 million in Q3 2025.